Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy

Next Previous
Trial Profile

A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABD 147 (Primary)
  • Indications Large cell carcinoma; Neuroendocrine carcinoma; Small cell lung cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors Abdera Therapeutics

Most Recent Events

  • 09 Sep 2025 According to Abdera Therapeutics media release, data from this study were presented in a poster session at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain.
  • 09 Sep 2025 Results published in the Media Release
  • 09 Sep 2025 According to Abdera Therapeutics media release, announced initial clinical data from its ongoing Phase 1a trial of ABD-147 in patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) the independent safety review committee recommended and support continued dose escalation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top